Ablynx NV (ABLX) - Financial and Strategic SWOT Analysis Review

June 2018 | 56 pages | ID: A40D5970E6DEN
GlobalData

Abstracts

Ablynx NV (ABLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ablynx NV (Ablynx) is a biopharmaceutical company that focuses on developing Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. Nanobodies are a novel class of antibody-derived therapeutic proteins which possess structural and functional properties of naturally-occurring heavy chain only antibodies. It has advantages of conventional antibodies along with the key features of small molecule drugs. Ablynx develops Nanobodies to treat serious human diseases including acquired thrombotic thrombocytopenic purpura (aTTp), psoriasis, bone disorders, cancer and pulmonary diseases. The company has ongoing research collaborations and significant partnerships with key pharmaceutical companies including Merck, Boehringer Ingelheim and Novartis. Ablynx is headquartered in Ghent, Belgium.

Ablynx NV Key Recent Developments

Feb 22,2018: ABLYNX ANNOUNCES 2017 FULL YEAR RESULTS
Feb 07,2018: Ablynx Announces Resignation of Dr Bo Jesper Hansen From the Board of Directors
Jan 24,2018: Ablynx Names Dr Robert Friesen as Chief Scientific Officer
Jan 08,2018: Ablynx Announces Board Changes
Dec 12,2017: Late-Breaking Clinical Trials Signal New Therapeutic Options for Many Patients in the Near Term

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Ablynx NV - Key Facts
Ablynx NV - Key Employees
Ablynx NV - Key Employee Biographies
Ablynx NV - Major Products and Services
Ablynx NV - History
Ablynx NV - Company Statement
Ablynx NV - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Ablynx NV - Business Description
Ablynx NV - Corporate Strategy
Ablynx NV - SWOT Analysis
SWOT Analysis - Overview
Ablynx NV - Strengths
Ablynx NV - Weaknesses
Ablynx NV - Opportunities
Ablynx NV - Threats
Ablynx NV - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Ablynx NV, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 22, 2018: ABLYNX ANNOUNCES 2017 FULL YEAR RESULTS
Feb 07, 2018: Ablynx Announces Resignation of Dr Bo Jesper Hansen From the Board of Directors
Jan 08, 2018: Ablynx Announces Board Changes
Dec 12, 2017: Late-Breaking Clinical Trials Signal New Therapeutic Options for Many Patients in the Near Term
Nov 16, 2017: Ablynx Announces Results For The First Nine Months Of 2017 And A Year-To-Date Business Update
Oct 06, 2017: Publication In Accordance With Article 14 Of The Belgian Law Of 2 May 2007 Regarding The Publication Of Major Shareholdings (The 'Transparency Law')
Aug 24, 2017: Ablynx Announces 2017 Half Year Results and Year-to-date Business Update
Jul 17, 2017: Ablynx Proposes Appointment of Mrs Hilde Windels as a New Independent Director
Jul 17, 2017: Ablynx Proposes Appointment of Mrs Hilde Windels as a New Independent Director
Jun 13, 2017: Ablynx Appoints Markus Ewert As Chief Business Officer

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Ablynx NV, Key Facts
Ablynx NV, Key Employees
Ablynx NV, Key Employee Biographies
Ablynx NV, Major Products and Services
Ablynx NV, History
Ablynx NV, Subsidiaries
Ablynx NV, Key Competitors
Ablynx NV, Ratios based on current share price
Ablynx NV, Annual Ratios
Ablynx NV, Annual Ratios (Cont.1)
Ablynx NV, Interim Ratios
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Ablynx NV, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Ablynx NV, Performance Chart (2013 - 2017)
Ablynx NV, Ratio Charts
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Ablynx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

VHSquared Ltd.
GlaxoSmithKline Plc
Crescendo Biologics Ltd.
Cell Medica Ltd
Camel-IDs SV/SA.